Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares saw unusually-high trading volume on Wednesday . Approximately 1,769,169 shares traded hands during mid-day trading, an increase of 103% from the previous session’s volume of 872,586 shares.The stock last traded at $2.07 and had previously closed at $2.09.
CNAT has been the topic of several recent research reports. FBR & Co restated an “outperform” rating and issued a $16.00 price target on shares of Conatus Pharmaceuticals in a research report on Tuesday, August 30th. Brean Capital set a $7.00 price objective on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 5th. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research report on Wednesday, August 10th. Finally, Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research report on Friday, July 1st. They set a “buy” rating on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $9.41.
The company’s market cap is $46.35 million. The company’s 50-day moving average is $1.91 and its 200-day moving average is $2.23.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.08. During the same quarter last year, the business earned ($0.31) EPS. On average, equities analysts predict that Conatus Pharmaceuticals Inc. will post ($1.34) earnings per share for the current year.
Several institutional investors have recently made changes to their positions in CNAT. AXA raised its position in shares of Conatus Pharmaceuticals by 1.4% in the second quarter. AXA now owns 1,085,775 shares of the biotechnology company’s stock worth $2,237,000 after buying an additional 14,939 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Conatus Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 448,938 shares of the biotechnology company’s stock worth $925,000 after buying an additional 15,300 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Conatus Pharmaceuticals by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 86,296 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,668 shares during the last quarter. Institutional investors own 22.80% of the company’s stock.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.